A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab
Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) MK-7339-001/ENGOT-OV43/GOG-3036